Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma
Open Access
- 1 September 2019
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 47, 89-97
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme United Kingdom
- Bristol-Myers Squibb
- Pfizer
- Amgen (NCT02014441)
- EMD Serono
This publication has 15 references indexed in Scilit:
- Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer PatientsClinical Cancer Research, 2017
- Targeted agents and immunotherapies: optimizing outcomes in melanomaNature Reviews Clinical Oncology, 2017
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaJournal of Clinical Oncology, 2015
- First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor ActivityMolecular Therapy, 2015
- Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanomaJournal for ImmunoTherapy of Cancer, 2014
- Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and NeckClinical Cancer Research, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic MelanomaJournal of Clinical Oncology, 2009
- A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating FactorClinical Cancer Research, 2006
- ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Therapy, 2003